Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rolapitant for CINV in Germ Cell Tumor Patients
NCT03960151Phase 2Withdrawn
- Start
- May 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of rolapitant in chemotherapy-induced nausea and vomiting (CINV). Primary endpoint: Complete Response Rate at 8 Days. Planned start May 2018; status: withdrawn.
02
Drugs
rolapitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT03960151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03960151.